Eli Lilly's retatrutide, a triple hormone receptor agonist, achieved a mean weight loss of 28.3% over 80 weeks at the highest dose in Phase 3 trials. The reduction surpasses results from other approved GLP-1 receptor agonists.
The trial enrolled patients with obesity, with the high-dose group showing the strongest efficacy. However, the therapy was linked to an increased severity of common side effects, particularly nausea and gastrointestinal distress, which may limit tolerability.
Lilly has not yet filed retatrutide for FDA approval. The drug is in late-stage development, and a regulatory submission could come within the next year if the company proceeds based on these data. A PDUFA date has not been set.
Obesity is a massive market, with GLP-1 drugs projected to exceed $100 billion in annual sales. Retatrutide's greater weight loss could position it ahead of Lilly's own tirzepatide and Novo Nordisk's semaglutide, but the side effect profile may narrow its addressable patient population.
Experts caution that the 28.3% figure reflects the highest dose only, and real-world adherence could be lower due to tolerability. The risk-benefit trade-off will be critical in regulatory review and payer decisions.